UNSPSC 51432101: Guabenxan

This classification denotes an antihypertensive agent with the molecular formula C10H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SAW16W26X6, chemically known as (1,4-benzodioxan-6-ylmethyl)guanidine but generally known as guabenxan, which bears US NIH Compound Identifier 28563. European Medicines Agency schedules Guabenxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07967MIG.

UNSPSC 51432101 Guabenxan is a Commodity code under which state and local governments procure emergency medications and pharmaceutical products for fire rescue services, health agencies, and multi-jurisdictional cooperative purchasing programs. Recent solicitations show procurement of specific advanced life support medications in unit quantities (such as epinephrine, labetalol, adenosine, and diltiazem) supplied through sealed competitive bids with firm pricing, shipping included, and expiration-date warranties, as well as generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesaler networks. The issuing bodies include municipal fire departments, state health agencies, and multi-state cooperative purchasing alliances; Tampa Fire Rescue (via the City of Tampa's Purchasing Department) and the Texas Health and Human Services Commission represent active buyers in this space, alongside the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which coordinates procurement across state and local facilities in multiple states including Oregon.

Geographic activity centers on Florida, Texas, and the Upper Midwest (Minnesota and affiliated cooperative members), with the most concrete recent opportunity being the City of Tampa's IFB for Advanced Life Support Medications (Solicitation 26P00188, due April 8, 2026, estimated contract value $40,000) requiring delivery within ten calendar days and nine-month minimum shelf life, awarded to the lowest responsive, responsible bidder with a one-year term plus renewal options. MMCAP's RFP (Solicitation S1070000015802, due March 26, 2026) targets generic multi-source pharmaceuticals and OTC products with a two-year initial term, evaluated primarily on price competitiveness (75 percent weight) and requiring vendors to maintain relationships with AmerisourceBergen, Cardinal Health, or Morris & Dickson as authorized wholesalers. The Texas HHS Commission's RFI (HHS0017013, posted March 27, 2026) represents exploratory procurement activity toward a future direct-to-manufacturer prescription program outside traditional PBM and GPO channels, with no current award value or formal competitive timeline specified.